89282-03-1

Basic information

• Product Name: 3-iodopyridin-4-ol
• Synonyms: 3-iodopyridin-4-ol;3-Iodo-4-hydroxypyridine
• CAS NO: 89282-03-1
• Molecular Formula: C₅H₄INO
• Molecular Weight: 220.993
• Mol File: 89282-03-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 303 °C(Solv: water (7732-18-5))
• Boiling Point: 263.4 °C at 760 mmHg
• Flash Point: 113.1 °C
• Appearance: /
• Density: 2.12 g/cm³
• Vapor Pressure: 0.0103mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.79±0.18(Predicted)
• CAS DataBase Reference: 3-iodopyridin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-iodopyridin-4-ol(89282-03-1)
• EPA Substance Registry System: 3-iodopyridin-4-ol(89282-03-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 89282-03-1(Hazardous Substances Data)

Usage

General Description

3-iodopyridin-4-ol, also known as 3-Iodo-4-pyridinol, is a chemical compound with the molecular formula C5H4IN2O. It is a derivative of pyridine and contains an iodine atom attached to the 3-position and a hydroxyl group attached to the 4-position of the pyridine ring. 3-iodopyridin-4-ol is used in organic synthesis and pharmaceutical research as a building block for various organic reactions and as a precursor for the synthesis of biologically active molecules. It has also been studied for its potential antifungal and anticancer properties, making it a valuable compound in medicinal chemistry and drug discovery efforts.

InChI:InChI=1/C5H4INO/c6-4-3-7-2-1-5(4)8/h1-3H,(H,7,8)

Upstream product

• 108-96-3 4-pyridone 
• 626-64-2 pyridin-4-ol 
• 497-19-8 sodium carbonate 

Downstream Products

• 89324-16-3 4-hydroxypyridine-3-carbonitrile 
• 63731-38-4 2-phenylfuro<3,2-c>pyridine 
• 1093064-77-7 2-(5-nitro-1-trityl-1H-indazol-3-yl)-furo[3,2-c]pyridine 
• 89167-34-0 4-chloro-3-iodopyridine 

Relevant articles and documents

Synthesis of Long Oxahelicenes by Polycyclization in a Flow Reactor

A series of oxahelicenes composed of ortho/meta-annulated benzene/pyridine and 2H-pyran rings were synthesized on the basis of the cobalt(I)-mediated (or rhodium(I)- or nickel(0)-mediated) double, triple, or quadruple [2+2+2] cycloisomerization of branched aromatic hexa-, nona-, or dodecaynes, thus allowing the construction of 6, 9, or 12 rings in a single operation. The use of a flow reactor was found to be beneficial for the multicyclization reactions. The stereogenic centers present in some of the oligoynes steered the helical folding in such a way that the final oxa[9]-, [13]-, [17]- and [19]helicenes were obtained in both enantiomerically and diastereomerically pure form. Specifically, the oxa[19]helicenes beat the current record in the length of a helicene backbone. Single-molecule conductivity was studied by the mechanically controllable break-junction method with a pyridooxa[9]helicene.

KINASE INHIBITORS AND USES THEREOF

The present invention relates to compounds of the general formula (A) and pharmaceutical compositions thereof that inhibit protein tyrosine activity. In particular the invention relates to said compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling. Said compounds and compositions are useful for the treatment of cell proliferative diseases and conditions.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.